A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole

Trial Profile

A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Everolimus (Primary) ; Capecitabine; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BOLERO-6
  • Sponsors Novartis
  • Most Recent Events

    • 01 Dec 2017 Last checked against ClinicalTrials.gov record.
    • 16 Oct 2017 Planned End Date changed from 30 Oct 2018 to 30 Apr 2018.
    • 06 Aug 2017 This trial has been completed in Ireland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top